Research - Pain Therapeutics (PTIE) and Durect (DRRX) just announced that Pfizer (PFE) will discontinue development of Remoxy (Extended-Release oxycodone) and will return all rights to Pain Therapeutics. Pain Therapeutics had the rights to … Continue Reading
Read nowLong Ideas - Shares of Pain Therapeutics (NASDAQ:PTIE) continue to rise as partner Pfizer (NYSE:PFE) continues to send signals that Remoxy’s New Drug Application (NDA) could be resubmitted … Continue Reading
Read nowLong Ideas - Analysts and investors are refocusing on the opportunity for Pain Therapeutics’ (NASDAQ:PTIE) lead drug candidate, Remoxy. Remoxy is an extended-release formulation of the widely used … Continue Reading
Read nowRecap - Despite this asset class having just entered human testing, there’s significant excitement surrounding the therapeutic potential of blocking CD47 and the “DO NOT EAT” signal … Continue Reading
Read nowInsights - Shares of biopharmaceutical company Zogenix, Inc. (ZGNX) are up 16% in trading on Wednesday after the company announced that a new, abuse-deterrent formulation of Zohydro … Continue Reading
Read nowRecap - We count at least nine failures of one sort or another (Complete Response Letters, failed trials) in the last five days from companies such as Pozen (POZN), … Continue Reading
Read nowRecap - We ended the week with some commentary based largely on the strength observed in recent biotech stocks immediately following financings. It’s the momentum behind recent secondary offerings – … Continue Reading
Read now
